相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
Alessandra Aiello et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)
T Cell Responses to SARS-CoV-2
Alessandro Sette et al.
ANNUAL REVIEW OF IMMUNOLOGY (2023)
COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA
Livio Pagano et al.
BLOOD (2022)
Effectiveness of the BNT162b2mRNA COVID-19 vaccine in patients with hematological neoplasms in a nationwide mass vaccination setting
Moshe Mittelman et al.
BLOOD (2022)
Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination
Yair Herishanu et al.
BLOOD (2022)
COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research
Lindsey Wang et al.
BLOOD REVIEWS (2022)
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
Vincenzo Marasco et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres
Ondrej Susol et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer
Lauren C. Shapiro et al.
CANCER CELL (2022)
Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults
Mark A. Brockman et al.
JOURNAL OF INFECTIOUS DISEASES (2022)
Humoral- and T-Cell Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
Carla Tortorella et al.
NEUROLOGY (2022)
Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis
Joanne S. K. Teh et al.
BLOOD ADVANCES (2022)
Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD ADVANCES (2022)
Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia
Cristina Bagacean et al.
BLOOD ADVANCES (2022)
Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies
Moraima Jimenez et al.
BLOOD ADVANCES (2022)
Antibody responses following third mRNA COVID-19 vaccination in patients with cancer and potential timing of a fourth vaccination
Sidse Ehmsen et al.
CANCER CELL (2022)
Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
Aaron Shengting Mai et al.
EUROPEAN JOURNAL OF CANCER (2022)
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
Jose Luis Pinana et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Efficiency decreases
Halane Vaillant-Roussel et al.
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)
Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review
Vanessa Piechotta et al.
BLOOD CANCER JOURNAL (2022)
SARS-CoV-2 humoral responses following booster BNT162b2 vaccination in patients with B-cell malignancies
Evangelos Terpos et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Immunogenicity and clinical efficacy of anti-SARS-CoV-2 vaccination in patients with hematological malignancies: Results of a prospective cohort study of 365 patients
Marco Salvini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2022)
Commercialized kits to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in health care workers
Monica Martinez-Gallo et al.
MEDICINA CLINICA (2022)
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
Alessandra Aiello et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2022)
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Sean H. Lim et al.
NATURE CANCER (2022)
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Daniel R. Feikin et al.
LANCET (2022)
Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer
Jane C. Figueiredo et al.
CANCER RESEARCH (2021)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan et al.
SCIENCE (2021)
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Livio Pagano et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Shuo Feng et al.
NATURE MEDICINE (2021)
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Einav G. Levin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
Rishi R. Goel et al.
SCIENCE (2021)
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2021)
WHO International Standard for anti-SARS-CoV-2 immunoglobulin
Paul A. Kristiansen et al.
LANCET (2021)
Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies
Paola Ghione et al.
BLOOD (2021)
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
Lee Greenberger et al.
CANCER CELL (2021)
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
Lee M. Greenberger et al.
CANCER CELL (2021)
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
Sidse Ehmsen et al.
CANCER CELL (2021)
The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses
Delia Goletti et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
Kazimieras Maneikis et al.
LANCET HAEMATOLOGY (2021)
Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms
Samah Alimam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Takuya Sekine et al.
CELL (2020)
Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies
Jacopo Mariotti et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)